Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$23.39M+260.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Badawi
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 186
- Beta
- 2.50
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.89
Financials
Revenue
$23.39M+260.0%Net Income
$-4.45MEBITDA
$-4.55MFree Cash Flow
$-5.68MEPS (diluted)
$-0.08Shares Outstanding (diluted)
54.51M+55.5%Operating Expenses
$25.26MCash & Debt
$79.75MRevenue by Segment (annual)
$77.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $77.36M | $-38.43M | $-0.74 |
| 2024 | $79.87M | $-51.51M | $-1.03 |
| 2023 | $81.06M | $-55.55M | $-1.14 |
| 2022 | $71.33M | $-86.24M | $-1.80 |
| 2021 | $48.96M | $-62.96M | $-1.33 |
| 2020 | $27.64M | $-34.69M | $-0.74 |
| 2019 | $23.35M | $-25.87M | $-0.55 |
| 2018 | $7.53M | $-14.29M | $-0.44 |
Valuation
SGHThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+33.33%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Negative
… Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab intern…
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·48d ago·Negative
… to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to stat…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.13 per share
Typical surprise +8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.08 vs $-0.18beat
- Wed, May 6$-0.24 vs $-0.19miss
- Wed, Mar 4$-0.08 vs $-0.15beat
- Thu, Nov 6$-0.16 vs $-0.26beat
- Thu, Aug 7$-0.23 vs $-0.25beat
- Thu, May 8$-0.28 vs $-0.29beat
Estimates and results for SGHT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SGHT officers and directors.
- Bought
- $1.4m
- Sold
- $2.7m
11 trades
44 trades
- Hayden Jeremy B.sold
- Badawi Davidsold
- Rodberg Jamessold
- Bauerlein Alisonsold
- Taylor Brentonsold
- Badawi Paulsold
- Encrantz Staffanbought
- Bauerlein Alisonsold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SGHT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.